Filana Therapeutics, Inc. FLNA
0.48 USD 0.00 (-0.04%)
At closeNov 12, 2026, 8:05 AM EST
0.48 -0.01 -1.47%
Pre-market · Nov 12, 8:05 AM ET
0.48 Day range 0.5099
0.43 52-week range 3.45
- YTD
- -75.65%
- 1 year
- -84.50%
News
globenewswire.com Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 13.2% to $1.29 during Wednesday's pre-market session. The company's market cap stands at $5.4 million. The company's, Q2 earnings came…
benzinga.com Filana Therapeutics Q3 EPS $(0.22) Beats $(0.24) Estimate Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. This is unchanged from the same period last year.
benzinga.com Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG)…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…
benzinga.com Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward The FDA lifted a clinical hold on Filana Therapeutics' IND application, allowing a Phase 2a trial for a TSC-related epilepsy treatment.
benzinga.com FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex
benzinga.com Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 18.18 percent. This is a 80.43 percent increase over losses of…- benzinga.com Maxim Group Reinstates Buy on Filana Therapeutics, Announces $5 Price Target Maxim Group analyst Jason McCarthy reinstates Filana Therapeutics (NASDAQ:FLNA) with a Buy and announces $5 price target.
benzinga.com Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 56.25 percent increase over losses of…
benzinga.com Filana Therapeutics Announces Publication In Epilepsia Of Preclinical Data Showing Simufilam Attenuated Seizure Progression In Mouse Model Of Severe TSC-Related Epilepsy Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent mannerResults confirm and extend…